@article {761,
	title = {Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.},
	journal = {Cancer Immunol Immunother},
	volume = {70},
	year = {2021},
	month = {2021 May},
	pages = {1177-1188},
	abstract = {<p>Immunotherapy has been one of the great advances in the recent years for the treatment of advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that has benefited most from this approach. Currently, the only validated companion diagnostic test for first-line immunotherapy in metastatic NSCLC patients is testing for programmed death ligand 1 (PD-L1) expression in tumor tissues. However, not all patients experience an effective response with the established selection criteria and immune checkpoint inhibitors (ICIs). Liquid biopsy offers a noninvasive opportunity to monitor disease in patients with cancer and identify those who would benefit the most from immunotherapy. This review focuses on the use of liquid biopsy in immunotherapy treatment of NSCLC patients. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and exosomes are promising tools for developing new biomarkers. We discuss the current application and future implementation of these parameters to improve therapeutic decision-making and identify the patients who will benefit most from immunotherapy.</p>},
	keywords = {Animals, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Cell-Free Nucleic Acids, Exosomes, Humans, Immunotherapy, Liquid Biopsy, Lung Neoplasms},
	issn = {1432-0851},
	doi = {10.1007/s00262-020-02752-z},
	author = {Brozos-V{\'a}zquez, Elena Mar{\'\i}a and D{\'\i}az-Pe{\~n}a, Roberto and Garc{\'\i}a-Gonz{\'a}lez, Jorge and Le{\'o}n-Mateos, Luis and Mondelo-Mac{\'\i}a, Patricia and Pe{\~n}a-Chilet, Maria and L{\'o}pez-L{\'o}pez, Rafael}
}
@article {445,
	title = {Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.},
	journal = {Oncotarget},
	volume = {7},
	year = {2016},
	month = {2016 Mar 15},
	pages = {12904-16},
	abstract = {<p>Lung cancer (LC) is responsible for most cancer deaths. One of the main factors contributing to the lethality of this disease is the fact that a large proportion of patients are diagnosed at advanced stages when a clinical intervention is unlikely to succeed. In this study, we evaluated the potential of metabolomics by 1H-NMR to facilitate the identification of accurate and reliable biomarkers to support the early diagnosis and prognosis of non-small cell lung cancer (NSCLC).We found that the metabolic profile of NSCLC patients, compared with healthy individuals, is characterized by statistically significant changes in the concentration of 18 metabolites representing different amino acids, organic acids and alcohols, as well as different lipids and molecules involved in lipid metabolism. Furthermore, the analysis of the differences between the metabolic profiles of NSCLC patients at different stages of the disease revealed the existence of 17 metabolites involved in metabolic changes associated with disease progression.Our results underscore the potential of metabolomics profiling to uncover pathophysiological mechanisms that could be useful to objectively discriminate NSCLC patients from healthy individuals, as well as between different stages of the disease. </p>},
	keywords = {Adult, Aged, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Disease Progression, Female, Humans, Lung Neoplasms, Male, metabolomics, Middle Aged, Proton Magnetic Resonance Spectroscopy},
	issn = {1949-2553},
	doi = {10.18632/oncotarget.7354},
	author = {Puchades-Carrasco, Leonor and Jantus-Lewintre, Eloisa and P{\'e}rez-Rambla, Clara and Garcia-Garcia, Francisco and Lucas, Rut and Calabuig, Silvia and Blasco, Ana and Dopazo, Joaquin and Camps, Carlos and Pineda-Lucena, Antonio}
}
